The Valley Desk

NCT05828069 · Interventional trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Overall registry status Recruiting

Phase 2

Conditions Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov